On Wednesday AC Immune (NASDAQ: ACIU) rose 0.84% to $7.19 with an insignificant trading volume of 30,887 shares when the average volume is 82,295. Today ACIU instantly jumped 62.17% premarket. What is driving it to rise so fast?
AC Immune starts phase 1b/2a clinical trial for the treatment of Alzheimer’s disease which is seemingly not real to be healed but can be prevented at early stages. The current phase uses anti-Tau vaccines ACI-35.030, which is developed in collaboration with Janssen Pharmaceuticals.
Not many biotech companies fighting against Alzheimer’s disease now as COVID-19 pandemic has created a brutal race in developing an effective vaccine as soon as possible. However, some investors prefer investing in other biotech companies that fight other serious diseases.